Gamma glutamyl transferase – an underestimated marker for cardiovascular disease and the metabolic syndrome

Authors

  • Manuela G Neuman In Vitro Drug Safety and Biotechnology and Department of Pharmacology and Toxicology, University of Toronto
  • Stephen Malnick
  • Lucy Chertin

DOI:

https://doi.org/10.18433/jpps30923

Abstract

Gamma glutamyl transferase (GGT) is an enzyme in glutathione and cysteine metabolism. GGT is a standard liver enzyme test reflecting biliary tract involvement. It also has a prooxoidant activity and a modulating influence on endothelia dysfunction. GGT is associated with the metabolic syndrome and is often elevated in patients with NAFLD.

There is also a role for GGT activity in several aspects cardiovascular disease. There is an association between elevated GGT and cardiovascular mortality, atrial fibrillation, exacerbation of congestive heart failure . In addition there is an association with obstructive sleep apnea.

We review the evidence available and suggest that there is a need for further assessing the use of GGT, together with the presence of the metabolic syndrome as a prognostic marker.

Downloads

Download data is not yet available.

Author Biography

Manuela G Neuman, In Vitro Drug Safety and Biotechnology and Department of Pharmacology and Toxicology, University of Toronto

CEO In Vitro Drug Safety and Biotechnology

Downloads

Published

2020-04-19

How to Cite

Neuman, M. G., Malnick, S., & Chertin, L. (2020). Gamma glutamyl transferase – an underestimated marker for cardiovascular disease and the metabolic syndrome. Journal of Pharmacy &Amp; Pharmaceutical Sciences, 23(1), 65–74. https://doi.org/10.18433/jpps30923

Issue

Section

Review Articles